4. Liu C, Lou Y, Lizee G, et al. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest, 2008, 118:1165-1175.
[2]
6. Byun M, Ma CS, Ak？ay A, et al. Inherited human OX40 deficiency underlying classic Kaposi sarcoma of childhood. J Exp Med, 2013, 210:1743-1759.
[3]
8. Croft M. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol, 2010, 28:57-78.
[4]
10. Taylor L, Schwarz H. Identification of a soluble OX40 isoform:development of a specific and quantitative immunoassay. J Immunol Methods, 2001, 255:67-72.
[5]
12. Ruby CE, Montler R, Zheng R, et al. IL-12 is required for anti-OX40-mediated CD4 T cell survival. J Immunol, 2008, 180:2140-2148.
[6]
13. Jenkins SJ, Perona-Wright G, Worsley AG, et al. Dendritic cell expression of OX40 ligand acts as a costimulatory, not polarizing, signal for optimal Th2 priming and memory induction in vivo. J Immunol, 2007, 179:3515-3523.
[7]
14. Gough MJ, Ruby CE, Redmond WL, et al. OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res, 2008, 68:5206-5215.
[8]
15. Ruby CE, Redmond WL, Haley D, et al. Anti-OX40 stimulation in vivo enhances CD8+memory T cell survival and significantly increases recall responses. Eur J Immunol, 2007, 37:157-166.
[9]
17. Xiao X, Gong W, Demirci G, et al. New insights on OX40 in the control of T cell immunity and immune tolerance in vivo. J Immunol, 2012, 188:892-901.
[10]
19. Manku H, Graham DS, Vyse TJ. Association of the co-stimulator OX40L with systemic lupus erythematosus. J Mol Med (Berl), 2009, 87:229-234.
[11]
22. Rogers PR, Song J, Gramaglia I, et al. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity, 2001, 15:445-455.
[12]
25. Griseri T, Asquith M, Thompson C, et al. OX40 is required for regulatory T cell-mediated control of colitis. J Exp Med, 2010, 207:699-709.
[13]
27. Croft M, So T, Duan W, et al. The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev, 2009, 229:173-191.
[14]
29. Lei W, Zeng DX, Zhu CH, et al. The upregulated expression of OX40/OX40L and their promotion of T cells proliferation in the murine model of asthma. J Thorac Dis, 2014, 6:979-987.
[15]
30. Lei W, Zhu CH, Zeng da X, et al. SOX40L: an important inflammatory mediator in adult bronchial asthma. Ann Acad Med Singapore, 2012, 41:200-204.
[16]
33. Arestides RS, He H, Westlake RM, et al. Costimulatory molecule OX40L is critical for both Th1 and Th2 responses in allergic inflammation. Eur J Immunol, 2002, 32:2874-2880.
[17]
34. Seshasayee D, Lee WP, Zhou M, et al. In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation. J Clin Invest, 2007, 117:3868-3878.
1. Hanania NA. Targeting airway inflammation in asthma: current and future therapies. Chest, 2008, 133:989-998.
[20]
2. Cavanagh MM, Hussell T. Is it wise to target the late costimulatory molecule OX40 as a therapeutic target? Arch Immunol Ther Exp (Warsz), 2008, 56:291-297.
[21]
3. So T, Lee SW, Croft M. Immune regulation and control of regulatory T cells by OX40 and 4-1BB. Cytokine Growth Factor Rev, 2008, 19:253-262.
[22]
5. Siddiqui S, Mistry V, Doe C, et al. Airway wall expression of OX40/OX40L and interleukin-4 in asthma. Chest, 2010, 137:797-804.
[23]
7. Verdeil G, Puthier D, Nguyen C, et al. STAT5-mediated signals sustain a TCR-initiated gene expression program toward differentiation of CD8 T cell effectors. J Immunol, 2006, 176:4834-4842.
[24]
9. Kurche JS, Haluszczak C, McWilliams JA, et al. Type I IFN-dependent T cell activation is mediated by IFN-dependent dendritic cell OX40 ligand expression and is independent of T cell IFNR expression. J Immunol, 2012, 188:585-593.
[25]
11. Song J, So T, Cheng M, et al. Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion. Immunity, 2005, 22:621-631.
[26]
16. Huddleston CA, Weinberg AD, Parker DC. OX40 (CD134) engagement drives differentiation of CD4+T cells to effector cells. Eur J Immunol, 2006, 36:1093-1103.
[27]
18. Schwarz H. Biological activities of reverse signal transduction through CD137 ligand. J Leukoc Biol, 2005, 77:281-286.
[28]
20. Wang Q, Chen Y, Ge Y, et al. Characterization and functional study of five novel monoclonal antibodies against human OX40L highlight reverse signalling: enhancement of IgG production of B cells and promotion of maturation of DCs. Tissue Antigens, 2004, 64:566-574.
[29]
21. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol, 2004, 5:987-995.
[30]
23. Obermeier F, Schwarz H, Dunger N, et al. OX40/OX40L interaction induces the expression of CXCR5 and contributes to chronic colitis induced by dextran sulfate sodium in mice. Eur J Immunol, 2003, 33:3265-3274.
[31]
24. Djiki？ J, Nacka-Aleksi？ M, Pilipovi？ I, et al. Age-associated changes in rat immune system: lessons learned from experimental autoimmune encephalomyelitis. Exp Gerontol, 2014, 58:179-197.
[32]
26. Song J, So T, Croft M. Activation of NF-κB1 by OX40 contributes to antigen-driven T cell expansion and survival. J Immunol, 2008, 180:7240-7248.
31. Ezzat MH, Imam SS, Shaheen KY, et al. Serum OX40 ligand levels in asthmatic children:a potential biomarker of severity and persistence. Allergy Asthma Proc, 2011, 32:313-318.
[35]
32. Hoshino A, Tanaka Y, Akiba H, et al. Critical role for OX40 ligand in the development of pathogenic Th2 cells in a murine model of asthma. Eur J Immunol, 2003, 33:861-869.
[36]
35. Gauvreau GM, Boulet LP, Cockcroft DW, et al. OX40L blockade and allergen-induced airway responses in subjects with mild asthma. Clin Exp Allergy, 2014, 44:29-37.
[37]
37. Webb GJ, Hirschfield GM, Lane PJ. OX40, OX40L and autoimmunity:a comprehensive review. Clin Rev Allergy Immunol, 2015.[Epub ahead of print].
